Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLVR NASDAQ:IMTX NASDAQ:RACA NASDAQ:THCA NASDAQ:TMTS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLVRClever Leaves$0.00$0.00▼$1.00N/A3656.771,305 shs25 shsIMTXImmatics$10.51-3.0%$6.96$3.30▼$11.25$1.28B1.22807,887 shs376,705 shsRACATherapeutics Acquisition$9.53$9.81▼$21.44$175.51MN/A105,531 shsN/ATHCATuscan Holdings Corp. II$10.47$10.46$10.18▼$13.77$77.02M0.11117,672 shs310 shsTMTSSpartacus Acquisition$10.86$10.48$9.65▼$11.03$217.20MN/A95,063 shs78,933 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLVRClever Leaves0.00%0.00%-75.00%-50.00%-66.67%IMTXImmatics+6.49%+4.44%+90.00%+74.40%+14.12%RACATherapeutics Acquisition0.00%0.00%0.00%0.00%0.00%THCATuscan Holdings Corp. II0.00%0.00%0.00%0.00%0.00%TMTSSpartacus Acquisition0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLVRClever Leaves$0.00$0.00▼$1.00N/A3656.771,305 shs25 shsIMTXImmatics$10.51-3.0%$6.96$3.30▼$11.25$1.28B1.22807,887 shs376,705 shsRACATherapeutics Acquisition$9.53$9.81▼$21.44$175.51MN/A105,531 shsN/ATHCATuscan Holdings Corp. II$10.47$10.46$10.18▼$13.77$77.02M0.11117,672 shs310 shsTMTSSpartacus Acquisition$10.86$10.48$9.65▼$11.03$217.20MN/A95,063 shs78,933 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLVRClever Leaves0.00%0.00%-75.00%-50.00%-66.67%IMTXImmatics+6.49%+4.44%+90.00%+74.40%+14.12%RACATherapeutics Acquisition0.00%0.00%0.00%0.00%0.00%THCATuscan Holdings Corp. II0.00%0.00%0.00%0.00%0.00%TMTSSpartacus Acquisition0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLVRClever Leaves 0.00N/AN/AN/AIMTXImmatics 2.71Moderate Buy$13.6730.10% UpsideRACATherapeutics Acquisition 0.00N/AN/AN/ATHCATuscan Holdings Corp. II 0.00N/AN/AN/ATMTSSpartacus Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CLVR, TMTS, RACA, THCA, and IMTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/13/2025IMTXImmaticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold10/8/2025IMTXImmaticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025IMTXImmaticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/18/2025IMTXImmaticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.008/15/2025IMTXImmaticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLVRClever Leaves$17.42M0.00N/AN/A$14.02 per share0.00IMTXImmatics$130.13M9.81$0.25 per share41.62$5.12 per share2.05RACATherapeutics AcquisitionN/AN/AN/AN/AN/AN/ATHCATuscan Holdings Corp. IIN/AN/A$0.37 per share27.93($0.67) per shareN/ATMTSSpartacus AcquisitionN/AN/AN/AN/A$0.25 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLVRClever Leaves-$17.90M-$11.31N/AN/AN/AN/AN/AN/AN/AIMTXImmatics$16.47M-$0.65N/AN/AN/A-59.29%-15.60%-12.31%11/17/2025 (Estimated)RACATherapeutics AcquisitionN/AN/A0.00N/AN/AN/AN/AN/AN/ATHCATuscan Holdings Corp. II$1.78MN/A0.00∞N/AN/A-6.82%0.33%N/ATMTSSpartacus Acquisition-$3.73MN/A0.00∞N/AN/AN/AN/AN/ALatest CLVR, TMTS, RACA, THCA, and IMTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q1 2025IMTXImmatics-$0.38-$0.66-$0.28-$0.66$13.05 million$6.48 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLVRClever LeavesN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/ARACATherapeutics AcquisitionN/AN/AN/AN/AN/ATHCATuscan Holdings Corp. IIN/AN/AN/AN/AN/ATMTSSpartacus AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLVRClever LeavesN/AN/AN/AIMTXImmaticsN/A8.808.80RACATherapeutics AcquisitionN/A0.130.13THCATuscan Holdings Corp. IIN/A0.060.06TMTSSpartacus Acquisition0.060.300.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLVRClever Leaves6.92%IMTXImmatics64.41%RACATherapeutics AcquisitionN/ATHCATuscan Holdings Corp. II16.09%TMTSSpartacus Acquisition91.85%Insider OwnershipCompanyInsider OwnershipCLVRClever Leaves8.20%IMTXImmatics3.30%RACATherapeutics AcquisitionN/ATHCATuscan Holdings Corp. II61.00%TMTSSpartacus AcquisitionN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLVRClever Leaves5601.76 million1.61 millionNo DataIMTXImmatics260121.55 million117.54 millionOptionableRACATherapeutics AcquisitionN/A14.04 millionN/ANot OptionableTHCATuscan Holdings Corp. IIN/A7.36 million2.87 millionNot OptionableTMTSSpartacus Acquisition220.00 millionN/ANot OptionableCLVR, TMTS, RACA, THCA, and IMTX HeadlinesRecent News About These CompaniesSpartacus (1960)July 28, 2024 | moviefone.comMMajestic Gold flags potential China acquisitionApril 12, 2024 | miningweekly.comSpartacus Slots Review 2023 – Play For a Generous 95.98% RTP PayoutMay 8, 2023 | basketballinsiders.comBGary Lineker the Spartacus of the social media ageMarch 20, 2023 | belfasttelegraph.co.ukNextNav Announces Date for Third Quarter 2021 Earnings CallNovember 10, 2021 | finance.yahoo.comNextNav Named an IDC Innovator for Location and Geospatial DataNovember 8, 2021 | finance.yahoo.comNextNav and Spartacus Acquisition Corporation Announce Closing of Business CombinationOctober 28, 2021 | finance.yahoo.comTRX Systems Partners with NextNav to Enhance Situational Awareness for First RespondersOctober 20, 2021 | finance.yahoo.comTag: TMTS stockOctober 14, 2021 | stocksregister.comSLooking For A Top Momentum Stock? Check Out Spartacus Acquisition Corporation (NASDAQ: TMTS)October 14, 2021 | stocksregister.comSNextNav and Qualcomm Collaborate to Deliver Precise Vertical Location for E911 Emergency ServicesOctober 14, 2021 | finance.yahoo.comNextNav and Satelles Collaborate to Establish an Alternative PNT Testbed in the San Francisco Bay AreaOctober 5, 2021 | finance.yahoo.comNextNav Highlights Capabilities of its Nationwide Vertical Location Service at International Wireless Communications ExpoSeptember 30, 2021 | finance.yahoo.comNextNav Adds Decorated Marketing Executive, Gillian Smith, as Vice President of MarketingSeptember 29, 2021 | finance.yahoo.comNextNav Launches World’s First Integration of Vertical Location into Mobile Game, Atlas: Earth, Ushering in New Era of Immersive GamingSeptember 9, 2021 | finance.yahoo.comNextNav, a Leader in Next Generation GPS, to Host Virtual Investor Day on September 14, 2021August 25, 2021 | finance.yahoo.comNextNav Demonstrates World’s First GPS-Free PNT Network in DHS TrialAugust 19, 2021 | hstoday.usHSpartacus Acquisition Corp. Cl AAugust 18, 2021 | barrons.comNextNav Demonstrates World’s First GPS-Free PNT Network in Department of Homeland Security TrialAugust 16, 2021 | finance.yahoo.comNextNav Showcases Nationwide Vertical Location Service, Pinnacle, at NENA Conference and ExpoAugust 7, 2021 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Healthcare Stocks Using AI to Drive GrowthBy Chris Markoch | September 27, 2025Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut FrenzyBy Gabriel Osorio-Mazilli | September 21, 2025Is Intuitive Surgical the Hidden Winner in Healthcare’s Weakness?By Gabriel Osorio-Mazilli | October 1, 2025Palantir’s New Healthcare Deal Boosts AI and Data Reach By Chris Markoch | October 15, 20253 Lesser-Known Healthcare Names With Major Upside in StoreBy Nathan Reiff | October 2, 2025CLVR, TMTS, RACA, THCA, and IMTX Company DescriptionsClever Leaves NASDAQ:CLVRClever Leaves Holdings Inc. operates in the botanical cannabinoid and nutraceutical industries. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment cultivates, extracts, manufactures, commercializes, and distributes cannabinoid products comprising cannabis flowers, cannabidiol isolates, full spectrum and standardized extracts, and dry smokable flowers internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, distributes, and commercializes nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. It also produces extracted products, including isolates, crude oil extracts, and oral solutions; and tetrahydrocannabinol flowers. The company serves retail distributors, pharmaceutical and cannabis companies, and pharmacies. Clever Leaves Holdings Inc. was founded in 2017 and is based in Tocancipá, Colombia.Immatics NASDAQ:IMTX$10.50 -0.33 (-3.00%) As of 02:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Therapeutics Acquisition NASDAQ:RACATherapeutics Acquisition Corp., doing business as Research Alliance Corp. I, does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the healthcare industry in the United States. The company was incorporated in 2020 and is based in Boston, Massachusetts.Tuscan Holdings Corp. II NASDAQ:THCATuscan Holdings Corp. II does not have significant operations. It intends to merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities in the cannabis industry. The company was incorporated in 2019 and is based in New York, New York. Tuscan Holdings Corp. II operates as a subsidiary of Tuscan Holdings Acquisition II LLC.Spartacus Acquisition NASDAQ:TMTSSpartacus Acquisition Corporation does not have significant operations. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Duluth, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Why Analysts Are Upgrading Ratings After Klarna's IPO 3 Healthcare Companies Insiders Are Buying Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
